Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Business Wire
More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today more than 15 abstracts featuring its urology portfolio will be presented at the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU). The abstracts span studies across prostate and bladder cancers, featuring real-world data for Decipher Prostate and new insights from phase II clinical trials, including one utilizing the company’s upcoming TrueMRD™ Muscle-Invasive Bladder Cancer (MIBC) test. Collectively, these studies highlight how Veracyte’s Decipher and TrueMRD genomic tests are increasingly helping to guide clinical decision-making, advance biological understanding, and accelerate innovation in urologic cancer care. The conference will take place February 26-28 in San Francisco.“The breadt
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Veracyte (VCYT) had its price target raised by Needham & Company LLC from $44.00 to $48.00. They now have a "buy" rating on the stock.MarketBeat
- Veracyte Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Veracyte outlines 10%–13% revenue growth for 2026 while advancing MRD and Prosigna launches [Seeking Alpha]Seeking Alpha
- Veracyte (VCYT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Veracyte: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
VCYT
Earnings
- 2/25/26 - Beat
VCYT
Sec Filings
- 2/26/26 - Form 10-K
- 2/25/26 - Form 8-K
- 2/5/26 - Form SCHEDULE
- VCYT's page on the SEC website